Aridis Pharmaceuticals Inc. · OTC:ARDS
Aridis Pharmaceuticals — Investor Presentation (June 2020)
8 slides from Aridis Pharmaceuticals's investor presentation, Jun 26, 2020
Slide 1: Forward-Looking Statements
Forward-Looking Statements These forward-looking statements relate to future events or future financial performance of the Company. All such forward-looking statements involve risks and uncertainties and are not guaranties of future performance. An investment in the securities of Aridis is speculati
Slide 2: Rapid Discovery, Development & Manufacturing Platform for mAbs (PEX)
Rapid Discovery, Development & Manufacturing Platform for mAbs (PEXTM) Aridis Pharmaceuticals 3
Slide 3: Future Proofing mAbs for COVID-19/20/21 (AR-701)
Future Proofing mAbs for COVID-19/20/21 (AR-701) Cocktail of mAbs to several SARS-CoV-2 envelope proteins • • • • Convalescent COVID-19 patients-derived using PEXTM mAb discovery platform Multiple mAbs directed at conserved regions to enable broad coverage against variants Up to year-long protection
Slide 4: Novel Anti-infectives Focusing on Lung Infections
Novel Anti-infectives Focusing on Lung Infections Anti-bacterials Anti-virals AR-301 S. aureus mAb [Ph3] AR-101 P. aeruginosa mAb [Ph2] AR-501 cystic fibrosis [Ph1/2] AR-701 COVID-19 mAb [PC] AR-201 RSV mAb [PC] Aridis Pharmaceuticals 5
Slide 5: Clinical Anti-bacterial Programs for Lung Infections
Clinical Anti-bacterial Programs for Lung Infections Antibiotics: 1 molecular target Broad spectrum mAbs: 1 molecular target Narrow spectrum Small molecule: Many molecular targets Broad spect.: Anti-S. aureus Immunotherapy using monoclonal antibody from convalescent patients [AR-301] About 30% of ba
Slide 6: Lead Phase Clinical Program: AR-301 anti-S. aureus mAb
Lead Phase 3 Clinical Program: AR-301 anti-S. aureus mAb • • • Anti-S. aureus alphatoxin mAb being clinically evaluated as superiority trial in VAP patients Fully human mAb discovered from convalescent pneumonia patient S. aureus is a common bacterial agent in COVID-19 patients Ph2 data: Trend towar
Slide 7: Phase 1/2 Clinical Program: AR-501 Inhaled Gallium Citrate
Phase 1/2 Clinical Program: AR-501 Inhaled Gallium Citrate Mechanism of action: iron analog, subverts multiple key functions in bacteria Once-per-week inhaled therapy for chronic treatment On-going Phase 1/2 supported by CF Foundation of bacterial infection in CF Phase 2 proxy data of IV formulation
Slide 8: Phase 1/2 Clinical Program: AR-501 Inhaled Gallium Citrate
Phase 1/2 Clinical Program: AR-501 Inhaled Gallium Citrate ™ Mechanism of action: iron analog, subverts multiple key functions in bacteria ™ Once-per-week inhaled therapy for chronic treatment of bacterial infection in CF ™ On-going Phase 1/2 supported by CF Foundation Phase 2 proxy data of IV formu
Aridis Pharmaceuticals — Investor Presentation (June 2020) on 6ix